
Orthofix Medical OFIX
$ 11.79
2.25%
Annual report 2025
added 02-24-2026
Orthofix Medical Book Value 2011-2026 | OFIX
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Orthofix Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 450 M | 503 M | 599 M | 337 M | 337 M | 357 M | 328 M | 335 M | 297 M | 263 M | 290 M | 300 M | 310 M | 399 M | 315 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 599 M | 263 M | 361 M |
Quarterly Book Value Orthofix Medical
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 442 M | 458 M | 458 M | 503 M | 526 M | 546 M | 570 M | 599 M | 615 M | 640 M | 664 M | 337 M | 334 M | - | 336 M | 337 M | 365 M | 362 M | 355 M | 357 M | 357 M | 357 M | 357 M | 328 M | 328 M | 328 M | 328 M | 335 M | 335 M | 335 M | 335 M | 297 M | 297 M | 297 M | 297 M | 263 M | 263 M | 263 M | 263 M | 290 M | 290 M | 290 M | 290 M | 300 M | 300 M | 300 M | 300 M | 296 M | 296 M | 296 M | 296 M | 356 M | 368 M | 368 M | 368 M | 292 M | 315 M | 315 M | 315 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 664 M | 263 M | 362 M |
Book Value of other stocks in the Medical devices industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Bruker Corporation
BRKR
|
1.82 B | $ 36.73 | -0.1 % | $ 5.47 K | ||
|
Boston Scientific Corporation
BSX
|
43.7 B | $ 62.21 | -0.97 % | $ 92.1 B | ||
|
AdaptHealth Corp.
AHCO
|
1.53 B | $ 12.22 | 1.58 % | $ 1.65 B | ||
|
ClearPoint Neuro
CLPT
|
28 M | $ 9.4 | 0.32 % | $ 266 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
196 M | - | - | $ 1.77 B | ||
|
CONMED Corporation
CNMD
|
1.03 B | $ 33.97 | -2.33 % | $ 1.05 B | ||
|
Apollo Endosurgery
APEN
|
32.6 M | - | - | $ 475 M | ||
|
Lianluo Smart Limited
LLIT
|
272 M | - | 24.59 % | $ 44.8 M | ||
|
Acutus Medical
AFIB
|
-879 K | - | -26.83 % | $ 2.62 M | ||
|
Avinger
AVGR
|
-6.2 M | - | -20.74 % | $ 369 K | ||
|
Cytosorbents Corporation
CTSO
|
5.9 M | $ 0.6 | 2.92 % | $ 37.3 M | ||
|
Axonics Modulation Technologies
AXNX
|
570 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
27.7 M | - | 1.37 % | $ 20.5 M | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
25.5 M | - | -5.86 % | $ 30.6 M | ||
|
Delcath Systems
DCTH
|
111 M | $ 9.73 | 1.04 % | $ 349 M | ||
|
BioSig Technologies
BSGM
|
133 M | - | 37.08 % | $ 85.7 M | ||
|
EDAP TMS S.A.
EDAP
|
56.9 M | $ 3.48 | 2.66 % | $ 130 M | ||
|
Edwards Lifesciences Corporation
EW
|
10.3 B | $ 80.91 | -0.17 % | $ 47.3 B | ||
|
Butterfly Network
BFLY
|
169 M | $ 4.14 | 0.73 % | $ 876 M | ||
|
FONAR Corporation
FONR
|
146 M | $ 18.59 | - | $ 122 M | ||
|
Cardiovascular Systems
CSII
|
249 M | - | 0.15 % | $ 844 M | ||
|
Cutera
CUTR
|
-172 M | - | -10.19 % | $ 1.99 M | ||
|
AxoGen
AXGN
|
129 M | $ 32.92 | -4.41 % | $ 1.52 B | ||
|
Helius Medical Technologies
HSDT
|
2.35 M | $ 1.97 | 5.91 % | $ 1.2 M | ||
|
CryoLife, Inc.
CRY
|
58.1 M | - | -4.14 % | $ 702 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.55 B | $ 9.28 | -2.62 % | $ 715 M | ||
|
Dynatronics Corporation
DYNT
|
3.26 M | - | 14.99 % | $ 929 K | ||
|
Inogen
INGN
|
192 M | $ 6.42 | 3.3 % | $ 171 M | ||
|
Align Technology
ALGN
|
3.85 B | $ 171.18 | 0.34 % | $ 12.8 B | ||
|
Eargo
EAR
|
101 M | - | - | $ 10.2 M | ||
|
IRIDEX Corporation
IRIX
|
4.92 M | $ 1.01 | 3.54 % | $ 17.1 M | ||
|
IRadimed Corporation
IRMD
|
94.6 M | $ 96.42 | 0.2 % | $ 1.23 B | ||
|
Integer Holdings Corporation
ITGR
|
1.75 B | $ 85.39 | -1.68 % | $ 2.97 B | ||
|
CHF Solutions, Inc.
CHFS
|
6.23 M | - | 1.15 % | $ 34.5 M | ||
|
OrthoPediatrics Corp.
KIDS
|
347 M | $ 15.93 | -0.81 % | $ 374 M | ||
|
Soliton, Inc.
SOLY
|
243 M | - | -1.42 % | $ 435 M | ||
|
Conformis
CFMS
|
54.2 M | - | - | $ 16.4 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
2.61 B | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
229 M | - | 0.03 % | $ 1.58 B | ||
|
LENSAR
LNSR
|
-12.2 M | $ 5.93 | -2.23 % | $ 70.9 M | ||
|
Misonix, Inc.
MSON
|
30.4 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
52.2 M | - | - | $ 111 M | ||
|
Pulmonx Corporation
LUNG
|
54.1 M | $ 1.39 | 4.51 % | $ 56.6 M | ||
|
Second Sight Medical Products
EYES
|
15.7 M | - | -0.97 % | $ 54.4 M | ||
|
Medtronic PLC
MDT
|
48.3 B | $ 86.32 | -0.36 % | $ 111 B | ||
|
MiMedx Group
MDXG
|
257 M | $ 3.91 | -0.38 % | $ 578 M | ||
|
Myomo
MYO
|
11.4 M | $ 0.69 | 3.25 % | $ 28.9 M | ||
|
Intersect ENT, Inc.
XENT
|
550 M | - | - | $ 955 M |